Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Q
Qian, Siqi
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1128
-
Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Siqi Qian
Favorite
1145
-
The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Siqi Qian
Favorite
1228
-
Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Siqi Qian
Favorite
Qiao, Chun
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1131
-
Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Chun Qiao
Favorite
Qi, Keqin
Janssen
2028
-
Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Keqin Qi
Favorite
Qin, Dongxia
1149
-
Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Dongxia Qin
Favorite
Qin, Shuchao
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1102
-
Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Shuchao Qin
Favorite
1103
-
Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Shuchao Qin
Favorite
1128
-
Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Shuchao Qin
Favorite
1145
-
The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Shuchao Qin
Favorite
1209
-
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Shuchao Qin
Favorite
1228
-
Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Shuchao Qin
Favorite
Qiu, Lugui
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
1127
-
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Lugui Qiu
Favorite
1214
-
An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Lugui Qiu
Favorite
2013
-
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Lugui Qiu
Favorite
2014
-
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Lugui Qiu
Favorite
Qiu, Tonglu
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1102
-
Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Tonglu Qiu
Favorite
1103
-
Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Tonglu Qiu
Favorite
1128
-
Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Tonglu Qiu
Favorite
1145
-
The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Tonglu Qiu
Favorite
1209
-
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Tonglu Qiu
Favorite
1228
-
Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Tonglu Qiu
Favorite
Qi, Wei
3009
-
Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Wei Qi
Favorite
Quataert, Sally
University of Rochester Medical Center
1139
-
Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Sally Quataert
Favorite
Querol Rivas, Juliana
Institut Pasteur de Montevideo
1037
-
Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Juliana Querol Rivas
Favorite
1054
-
The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Juliana Querol Rivas
Favorite
1144
-
Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Juliana Querol Rivas
Favorite
Quijada Álamo, Miguel
University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca
1161
-
ZMYM3
Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Miguel Quijada Álamo
Favorite
Quillet-Mary, Anne
CRCT/INSERM/CNRS/UPS
4002
-
Longitudinal CITE-Seq analyses of the peripheral blood identify transcriptomic signatures associated with progression and transformation under targeted therapy
Anne Quillet-Mary
Favorite
Qureshi, Zaina
Janssen Scientific Affairs, LLC
1204
-
Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
Zaina Qureshi
Favorite
2025
-
Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of first-line ibrutinib
Zaina Qureshi
Favorite
2026
-
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
Zaina Qureshi
Favorite
2027
-
Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database
Zaina Qureshi
Favorite
